- Home
- UNCY vs IMAB Comparison
UNCY vs IMAB Comparison
Compare UNCY & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- IMAB
- Stock Information
- Founded
- UNCY 2016
- IMAB 2014
- Country
- UNCY United States
- IMAB United States
- Employees
- UNCY N/A
- IMAB N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- UNCY Health Care
- IMAB Health Care
- Exchange
- UNCY Nasdaq
- IMAB Nasdaq
- Market Cap
- UNCY 71.8M
- IMAB 73.9M
- IPO Year
- UNCY 2021
- IMAB 2020
- Fundamental
- Price
- UNCY $0.62
- IMAB $0.88
- Analyst Decision
- UNCY Strong Buy
- IMAB Strong Buy
- Analyst Count
- UNCY 3
- IMAB 2
- Target Price
- UNCY $5.50
- IMAB $5.50
- AVG Volume (30 Days)
- UNCY 510.7K
- IMAB 160.3K
- Earning Date
- UNCY 05-16-2025
- IMAB 04-03-2025
- Dividend Yield
- UNCY N/A
- IMAB N/A
- EPS Growth
- UNCY N/A
- IMAB N/A
- EPS
- UNCY N/A
- IMAB N/A
- Revenue
- UNCY N/A
- IMAB N/A
- Revenue This Year
- UNCY N/A
- IMAB N/A
- Revenue Next Year
- UNCY $1,502.84
- IMAB N/A
- P/E Ratio
- UNCY N/A
- IMAB N/A
- Revenue Growth
- UNCY N/A
- IMAB N/A
- 52 Week Low
- UNCY $0.20
- IMAB $0.60
- 52 Week High
- UNCY $1.16
- IMAB $2.00
- Technical
- Relative Strength Index (RSI)
- UNCY 51.83
- IMAB 52.85
- Support Level
- UNCY $0.59
- IMAB $0.85
- Resistance Level
- UNCY $0.66
- IMAB $0.92
- Average True Range (ATR)
- UNCY 0.03
- IMAB 0.07
- MACD
- UNCY -0.00
- IMAB 0.01
- Stochastic Oscillator
- UNCY 40.05
- IMAB 48.17
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).